Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA.
Biotechnol J. 2012 Dec;7(12):1451-61. doi: 10.1002/biot.201200076.
There are a great variety of human membrane proteins, and these currently form the largest group of targets for marketed drugs. Despite the advances in drug design, however, promiscuity between drug molecules and targets often leads to undesired signaling effects, which result in unintended side effects. In this review, one family of membrane proteins - the G protein-coupled receptors (GPCRs) - is used as a model to review experimental techniques that may be used to examine the activity of membrane proteins. As these receptors are highly relevant to healthy human physiology and represent the largest family of drug targets, they represent an excellent model for membrane proteins in general. We also review experimental evidence that suggests there may be multiple ways to target a GPCR - and by extension, membrane proteins - to more effectively target unhealthy phenotypes while reducing the occurrence and severity of side effects.
有大量的人类膜蛋白,这些目前形成了上市药物的最大目标群体。然而,尽管在药物设计方面取得了进展,但药物分子与靶点之间的混杂性常常导致不理想的信号效应,从而导致意外的副作用。在这篇综述中,我们将使用膜蛋白家族中的一个模型——G 蛋白偶联受体(GPCR),来回顾可能用于研究膜蛋白活性的实验技术。由于这些受体与健康的人体生理学密切相关,并且代表了最大的药物靶点家族,因此它们是膜蛋白的一个很好的模型。我们还回顾了实验证据,表明可能有多种方法可以靶向 GPCR——并扩展到膜蛋白——以更有效地针对不健康表型,同时减少副作用的发生和严重程度。